In the sphere of immuno-oncology research, a powerful tool has emerged - the Diet-Induced Obesity (DIO) mouse model. These models provide researchers a practical route to understanding the connections between obesity, immunity, and cancer treatment. The real value of DIO mice lies in their ability to reflect human-like responses, marking a new phase of discovery. Below are the top 5 reasons researchers should be incorporating DIO mice into the preclinical evaluation of immuno-oncology treatments.
August 22, 2023
- Model Spotlight: Breast Cancer Clinical Update and Preclinical Plan
- Advancing Preclinical Research in Gynecologic Cancers
- History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
- Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
Model Spotlight: Breast Cancer Clinical Update and Preclinical Plan
Based on the American Cancer Society 2026 estimates and survival statistics, as of October 2026, developments in antibody-drug conjugates (ADCs), ...
Advancing Preclinical Research in Gynecologic Cancers
Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...
History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
